{
  "schema_version": "2.0",
  "description": "医渡科技有限公司的双语结构化披露数据，覆盖截至 2026 年 3 月 31 日止财年的最新年度业绩、三项医疗人工智能业务、YiduCore、客户覆盖、管理层、风险、现金流、股东回报及五年财务表现。",
  "description_en": "Bilingual structured disclosure data for Yidu Tech Inc., covering the latest fiscal-year results to 31 March 2026, its three medical-AI businesses, YiduCore, client reach, management, risks, cash flow, shareholder returns and five-year financial performance.",
  "scope": "Formal disclosure reviewed through 17 July 2026. FY2026 figures come from the 30 June 2026 annual results announcement; the latest complete annual report available at the review cutoff is the FY2025 annual report.",
  "methodology_url": "https://pureir.top/#method",
  "usage_notice": "PureIR 为独立、非官方信息平台。本数据用于帮助阅读正式披露，不构成投资建议，也不替代原始文件。",
  "usage_notice_en": "PureIR is an independent, unofficial information platform. This dataset supports reading of formal disclosure; it is not investment advice and does not replace the original filings.",
  "publisher": {
    "name": "PureIR",
    "url": "https://pureir.top/"
  },
  "data_as_of": "2026-03-31",
  "last_reviewed": "2026-07-17",
  "company": {
    "name": "Yidu Tech Inc.",
    "name_zh": "医渡科技有限公司",
    "stock_code": "02158",
    "exchange": "HKEX",
    "official_website": "https://www.yidutech.com/",
    "investor_relations_email": "ir@yidutech.com",
    "investor_relations_contact_url": "https://www.yidutech.com/",
    "investor_relations_email_source": {
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 162
    },
    "fiscal_year_end": "03-31",
    "fiscal_year_note": "医渡科技的财年于每年 3 月 31 日结束；FY2026 指 2025 年 4 月 1 日至 2026 年 3 月 31 日。",
    "fiscal_year_note_en": "Yidu Tech's fiscal year ends on 31 March; FY2026 covers 1 April 2025 through 31 March 2026.",
    "description": "医渡科技以 YiduCore 为医疗智能基础设施，业务覆盖医疗、生命科学与健康管理三项人工智能应用。2026 财年收入为人民币 819.298 百万元，年度利润为人民币 78.766 百万元，毛利率为 36.4%；截至 2026 年 3 月 31 日，公司服务 133 家中国头部医院及 54 家监管机构和政策制定者，覆盖超过 12,000 家医院。",
    "description_en": "Yidu Tech uses YiduCore as medical-intelligence infrastructure across AI for Medical, AI for Life Sciences and AI for Care. In FY2026 it reported revenue of RMB819.298 million, profit for the year of RMB78.766 million and a gross margin of 36.4%; at 31 March 2026 it served 133 top hospitals in China and 54 regulators and policymakers, covering more than 12,000 hospitals.",
    "summary_sources": [
      {
        "label": "2026 财年核心财务",
        "label_en": "FY2026 financial highlights",
        "source_type": "hkex_filing",
        "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
        "pdf_page": 1
      },
      {
        "label": "客户覆盖与运营规模",
        "label_en": "Client reach and operating scale",
        "source_type": "hkex_filing",
        "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
        "pdf_page": 3
      },
      {
        "label": "五年财务概要",
        "label_en": "Five-year financial summary",
        "source_type": "hkex_filing",
        "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
        "pdf_page": 268
      }
    ]
  },
  "highlights": [
    {
      "metric_id": "profit_for_year",
      "label": "年度利润",
      "label_en": "Profit for the year",
      "display": "RMB 78.8m",
      "display_en": "RMB78.8m",
      "period": "FY2026",
      "period_zh": "截至 2026 年 3 月 31 日止年度",
      "period_en": "Year ended 31 March 2026",
      "value": 78.766,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "2025 财年为亏损人民币 135.223 百万元；2026 财年公司首次实现全年盈利。",
      "detail_en": "FY2025 recorded a loss of RMB135.223 million; the company achieved its first full-year profit in FY2026.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "top_hospital_clients",
      "label": "中国头部医院客户",
      "label_en": "Top-hospital clients in China",
      "display": "133 家",
      "display_en": "133 hospitals",
      "period": "2026-03-31",
      "period_zh": "截至 2026 年 3 月 31 日",
      "period_en": "As at 31 March 2026",
      "value": 133,
      "currency": "N/A",
      "unit": "hospitals",
      "unit_display_zh": "家头部医院",
      "unit_display_en": "top hospitals",
      "detail": "AI for Medical 同时服务 54 家监管机构和政策制定者，解决方案覆盖超过 12,000 家医院。",
      "detail_en": "AI for Medical also served 54 regulators and policymakers, with solutions covering more than 12,000 hospitals.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "final_dividend_per_share",
      "label": "拟派末期股息",
      "label_en": "Proposed final dividend",
      "display": "HK$0.04 / 股",
      "display_en": "HK$0.04/share",
      "period": "FY2026",
      "period_zh": "截至 2026 年 3 月 31 日止年度",
      "period_en": "Year ended 31 March 2026",
      "value": 0.04,
      "currency": "HKD",
      "unit": "per share",
      "unit_display_zh": "每股港币",
      "unit_display_en": "HKD per share",
      "detail": "董事会建议，须经股东于 2026 年 8 月 28 日召开的股东周年大会批准。",
      "detail_en": "A Board recommendation subject to shareholder approval at the annual general meeting scheduled for 28 August 2026.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 22
    }
  ],
  "narrative": [
    {
      "title": "从减亏进入全年盈利",
      "title_en": "From narrowing losses to a full-year profit",
      "text": "2026 财年收入同比增长 14.6%，毛利同比增长 24.8%，毛利率由 33.5% 提升至 36.4%；年度利润转为人民币 78.766 百万元。同期全年经营现金净流出收窄至人民币 21.998 百万元，下半年经营现金流净额为正人民币 29.3 百万元。",
      "text_en": "FY2026 revenue increased by 14.6%, gross profit by 24.8% and gross margin rose from 33.5% to 36.4%; profit for the year turned positive at RMB78.766 million. Full-year net operating cash outflow narrowed to RMB21.998 million, while second-half net operating cash flow was positive at RMB29.3 million.",
      "period": "FY2026",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 2
    },
    {
      "title": "三项业务连接医疗、药企与健康管理",
      "title_en": "Three businesses connect care, life sciences and health management",
      "text": "AI for Medical、AI for Life Sciences 与 AI for Care 在 2026 财年分别实现收入人民币 381.034 百万元、270.416 百万元及 167.848 百万元，分别同比增长 10.2%、9.4% 及 37.6%。",
      "text_en": "AI for Medical, AI for Life Sciences and AI for Care generated FY2026 revenue of RMB381.034 million, RMB270.416 million and RMB167.848 million, increasing by 10.2%, 9.4% and 37.6%, respectively.",
      "period": "FY2026",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 1
    },
    {
      "title": "YiduCore 形成医疗智能基础设施",
      "title_en": "YiduCore as medical-intelligence infrastructure",
      "text": "截至 2026 年 3 月 31 日，YiduCore 累计处理及分析约 90 亿条经授权真实世界医疗记录，覆盖超过 13.2 亿人次就诊；专病库覆盖超过 100 个疾病领域。",
      "text_en": "At 31 March 2026, YiduCore had cumulatively processed and analysed approximately 9 billion authorised real-world medical records covering more than 1.32 billion patient visits; its specialised disease repository covered more than 100 disease categories.",
      "period": "2026-03-31",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    }
  ],
  "management": [
    {
      "name_zh": "宫盈盈（宫如璟）",
      "name_en": "Gong Yingying (Gong Rujing)",
      "role_zh": "创始人、董事会主席、执行董事",
      "role_en": "Founder, Chairlady and Executive Director",
      "bio_zh": "负责公司整体战略、业务方向及管理。公司 2025 年报披露其投资及行业经验，并确认徐济铭为其配偶。",
      "bio_en": "Responsible for the company's overall strategy, business direction and management. The FY2025 annual report describes her investment and industry experience and identifies Xu Jiming as her spouse.",
      "period": "Current roster at 30 June 2026; biography in FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 42,
      "additional_source_type": "hkex_filing",
      "additional_source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "additional_pdf_page": 36,
      "portrait_status": "official_company_website",
      "portrait_src": "/assets/management/yidutech-gong-yingying.webp",
      "portrait_alt_zh": "医渡科技官网发布的宫盈盈官方肖像",
      "portrait_alt_en": "Official portrait of Gong Yingying published by Yidu Tech",
      "portrait_width": 280,
      "portrait_height": 220,
      "portrait_source_url": "https://www.yidutech.com/en/investors6.html",
      "portrait_asset_url": "https://www.yidutech.com/uploads/20251210/543717a423c404afa7d480afb120f985.png",
      "portrait_source_type": "company_website",
      "portrait_reviewed": "2026-07-17"
    },
    {
      "name_zh": "徐济铭",
      "name_en": "Xu Jiming",
      "role_zh": "执行董事、首席执行官、联合创始人",
      "role_en": "Executive Director, Chief Executive Officer and Co-founder",
      "bio_zh": "2015 年加入集团，2023 年 2 月获委任为执行董事及首席执行官，负责领导与管理日常运营；拥有逾十年搜索引擎、大数据及人工智能经验。",
      "bio_en": "Joined the Group in 2015 and was appointed Executive Director and Chief Executive Officer in February 2023 to lead and manage daily operations; has more than ten years of experience in search-engine technology, big data and AI.",
      "period": "Current roster at 30 June 2026; biography in FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 43,
      "additional_source_type": "hkex_filing",
      "additional_source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "additional_pdf_page": 36,
      "portrait_status": "official_company_website",
      "portrait_src": "/assets/management/yidutech-xu-jiming.webp",
      "portrait_alt_zh": "医渡科技官网发布的徐济铭官方肖像",
      "portrait_alt_en": "Official portrait of Xu Jiming published by Yidu Tech",
      "portrait_width": 280,
      "portrait_height": 220,
      "portrait_source_url": "https://www.yidutech.com/en/investors6.html",
      "portrait_asset_url": "https://www.yidutech.com/uploads/20230201/b769a3572674f3ded2456d5413dbe561.jpg",
      "portrait_source_type": "company_website",
      "portrait_reviewed": "2026-07-17"
    },
    {
      "name_zh": "封晓瑛",
      "name_en": "Feng Xiaoying",
      "role_zh": "执行董事、首席财务官、联席公司秘书",
      "role_en": "Executive Director, Chief Financial Officer and Joint Company Secretary",
      "bio_zh": "2023 年 2 月获委任为执行董事、首席财务官及联席公司秘书；为加拿大特许专业会计师及中国注册会计师，曾任多家机构财务及管理职位。",
      "bio_en": "Appointed Executive Director, Chief Financial Officer and Joint Company Secretary in February 2023; is a Chartered Professional Accountant of Canada and a PRC Certified Public Accountant, with prior finance and management roles at several institutions.",
      "period": "Current roster at 30 June 2026; biography in FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 43,
      "additional_source_type": "hkex_filing",
      "additional_source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "additional_pdf_page": 36,
      "portrait_status": "official_company_website",
      "portrait_src": "/assets/management/yidutech-feng-xiaoying.webp",
      "portrait_alt_zh": "医渡科技官网发布的封晓瑛官方肖像",
      "portrait_alt_en": "Official portrait of Feng Xiaoying published by Yidu Tech",
      "portrait_width": 280,
      "portrait_height": 230,
      "portrait_source_url": "https://www.yidutech.com/en/investors6.html",
      "portrait_asset_url": "https://www.yidutech.com/uploads/20230201/6fc0124f93b5c689cac20728ff66fb9e.jpg",
      "portrait_source_type": "company_website",
      "portrait_reviewed": "2026-07-17"
    }
  ],
  "risks": [
    {
      "title": "技术迭代与商业执行",
      "title_en": "Technology iteration and commercial execution",
      "text": "公司将跟上人工智能、大数据分析及其他技术的快速变化，以及管理业务增长与扩张，列为主要风险与不确定性。",
      "text_en": "The company identifies keeping pace with rapid changes in AI, big-data analytics and other technologies, together with managing business growth and expansion, as principal risks and uncertainties.",
      "period": "FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 28
    },
    {
      "title": "医疗数据、隐私与许可",
      "title_en": "Healthcare data, privacy and licences",
      "text": "持续获取并准确、高效处理医疗数据、遵守数据保护及隐私法规，以及取得并维持业务所需许可、批准与批文，均属于正式披露的主要风险。",
      "text_en": "Continued access to and accurate, efficient processing of healthcare data, compliance with data-protection and privacy laws, and obtaining and maintaining required licences, permits and approvals are formally disclosed principal risks.",
      "period": "FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 28
    },
    {
      "title": "合约安排结构",
      "title_en": "Contractual-arrangement structure",
      "text": "公司披露，若中国监管机构认定相关合约安排不符合适用规定，或法规解释发生变化，可能带来包括安排失效及放弃相关经营权益在内的严重后果；合约控制也可能不及直接所有权有效。",
      "text_en": "The company discloses that an adverse PRC regulatory finding or change in interpretation could result in severe consequences, including invalidation of contractual arrangements and loss of interests in relevant operations; contractual control may also be less effective than direct ownership.",
      "period": "FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 31
    },
    {
      "title": "应收款项与信用风险",
      "title_en": "Receivables and credit risk",
      "text": "集团的信用风险主要涉及银行存款、合约资产、贸易应收款及其他按摊销成本计量的金融资产；贸易应收款及合约资产采用预期信用损失模型计量减值。",
      "text_en": "The Group's credit risk principally relates to bank deposits, contract assets, trade receivables and other financial assets at amortised cost; trade receivables and contract assets are assessed under an expected-credit-loss model.",
      "period": "FY2025 annual report",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 205
    }
  ],
  "reports": [
    {
      "year": 2025,
      "published": "2025-07-25",
      "title": "FY2025 Annual Report",
      "title_zh": "2025 财年年报",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pages": 274
    },
    {
      "year": 2024,
      "published": "2024-07-26",
      "title": "FY2024 Annual Report",
      "title_zh": "2024 财年年报",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0726/2024072600647.pdf",
      "pages": 268
    },
    {
      "year": 2023,
      "published": "2023-07-27",
      "title": "FY2023 Annual Report",
      "title_zh": "2023 财年年报",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0727/2023072701144.pdf",
      "pages": 256
    },
    {
      "year": 2022,
      "published": "2022-07-28",
      "title": "FY2022 Annual Report",
      "title_zh": "2022 财年年报",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0728/2022072801344.pdf",
      "pages": 260
    }
  ],
  "announcements": [
    {
      "id": "annual-results-2026",
      "published": "2026-06-30",
      "title": "Annual Results Announcement for the Fiscal Year Ended 31 March 2026",
      "title_zh": "截至 2026 年 3 月 31 日止财年年度业绩公告",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pages": 36
    }
  ],
  "financials": [
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2022",
      "period_start": "2021-04-01",
      "period_end": "2022-03-31",
      "value": 1237.2,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2022",
      "period_start": "2021-04-01",
      "period_end": "2022-03-31",
      "value": 399.445,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "profit_for_year",
      "label": "年度利润／（亏损）",
      "label_en": "Profit/(loss) for the year",
      "period": "FY2022",
      "period_start": "2021-04-01",
      "period_end": "2022-03-31",
      "value": -766.36,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2023",
      "period_start": "2022-04-01",
      "period_end": "2023-03-31",
      "value": 804.7,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2023",
      "period_start": "2022-04-01",
      "period_end": "2023-03-31",
      "value": 274.53,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "profit_for_year",
      "label": "年度利润／（亏损）",
      "label_en": "Profit/(loss) for the year",
      "period": "FY2023",
      "period_start": "2022-04-01",
      "period_end": "2023-03-31",
      "value": -632.361,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2024",
      "period_start": "2023-04-01",
      "period_end": "2024-03-31",
      "value": 807.076,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2024",
      "period_start": "2023-04-01",
      "period_end": "2024-03-31",
      "value": 339.445,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "profit_for_year",
      "label": "年度利润／（亏损）",
      "label_en": "Profit/(loss) for the year",
      "period": "FY2024",
      "period_start": "2023-04-01",
      "period_end": "2024-03-31",
      "value": -221.242,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2025",
      "period_start": "2024-04-01",
      "period_end": "2025-03-31",
      "value": 714.979,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2025",
      "period_start": "2024-04-01",
      "period_end": "2025-03-31",
      "value": 239.182,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "profit_for_year",
      "label": "年度利润／（亏损）",
      "label_en": "Profit/(loss) for the year",
      "period": "FY2025",
      "period_start": "2024-04-01",
      "period_end": "2025-03-31",
      "value": -135.223,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 268
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2026",
      "period_start": "2025-04-01",
      "period_end": "2026-03-31",
      "value": 819.298,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 24
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2026",
      "period_start": "2025-04-01",
      "period_end": "2026-03-31",
      "value": 298.496,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 24
    },
    {
      "metric_id": "profit_for_year",
      "label": "年度利润／（亏损）",
      "label_en": "Profit/(loss) for the year",
      "period": "FY2026",
      "period_start": "2025-04-01",
      "period_end": "2026-03-31",
      "value": 78.766,
      "currency": "RMB",
      "unit": "million",
      "comparability_note_zh": "FY2026 为 2025 年 4 月 1 日至 2026 年 3 月 31 日；公司实现上市后首次全年盈利。",
      "comparability_note_en": "FY2026 covers 1 April 2025 through 31 March 2026; the company reported its first full-year profit since listing.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 24
    }
  ],
  "business_revenue": [
    {
      "metric_id": "ai_for_medical_revenue",
      "label": "AI for Medical 收入",
      "label_en": "AI for Medical revenue",
      "period": "FY2025",
      "value": 345.888,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    },
    {
      "metric_id": "ai_for_life_sciences_revenue",
      "label": "AI for Life Sciences 收入",
      "label_en": "AI for Life Sciences revenue",
      "period": "FY2025",
      "value": 247.112,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    },
    {
      "metric_id": "ai_for_care_revenue",
      "label": "AI for Care 收入",
      "label_en": "AI for Care revenue",
      "period": "FY2025",
      "value": 121.979,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    },
    {
      "metric_id": "ai_for_medical_revenue",
      "label": "AI for Medical 收入",
      "label_en": "AI for Medical revenue",
      "period": "FY2026",
      "value": 381.034,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    },
    {
      "metric_id": "ai_for_life_sciences_revenue",
      "label": "AI for Life Sciences 收入",
      "label_en": "AI for Life Sciences revenue",
      "period": "FY2026",
      "value": 270.416,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    },
    {
      "metric_id": "ai_for_care_revenue",
      "label": "AI for Care 收入",
      "label_en": "AI for Care revenue",
      "period": "FY2026",
      "value": 167.848,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 30
    }
  ],
  "operating_metrics": [
    {
      "metric_id": "top_hospital_clients",
      "label": "中国头部医院客户",
      "label_en": "Top-hospital clients in China",
      "period": "2026-03-31",
      "value": 133,
      "currency": "N/A",
      "unit": "hospitals",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "regulator_clients",
      "label": "监管机构和政策制定者客户",
      "label_en": "Regulator and policymaker clients",
      "period": "2026-03-31",
      "value": 54,
      "currency": "N/A",
      "unit": "organisations",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "hospitals_covered",
      "label": "解决方案覆盖医院",
      "label_en": "Hospitals covered by solutions",
      "period": "2026-03-31",
      "value": 12000,
      "currency": "N/A",
      "unit": "hospitals",
      "comparability_note": "More than 12,000 hospitals were covered.",
      "comparability_note_zh": "披露口径为覆盖超过 12,000 家医院。",
      "comparability_note_en": "More than 12,000 hospitals were covered.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "life_science_clients",
      "label": "生命科学客户",
      "label_en": "Life-sciences clients",
      "period": "FY2026",
      "value": 98,
      "currency": "N/A",
      "unit": "clients",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "clinical_studies",
      "label": "完成临床研究",
      "label_en": "Clinical studies completed",
      "period": "FY2026",
      "value": 516,
      "currency": "N/A",
      "unit": "studies",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "active_health_platform_users",
      "label": "健康管理平台活跃用户",
      "label_en": "Active health-platform users",
      "period": "2026-03-31",
      "value": 22,
      "currency": "N/A",
      "unit": "million users",
      "comparability_note": "The disclosed number surpassed 22 million.",
      "comparability_note_zh": "披露口径为超过 2,200 万名活跃用户。",
      "comparability_note_en": "The disclosed number surpassed 22 million.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "authorised_medical_records",
      "label": "累计处理及分析授权医疗记录",
      "label_en": "Authorised medical records processed and analysed",
      "period": "2026-03-31",
      "value": 9,
      "currency": "N/A",
      "unit": "billion records",
      "comparability_note": "The company disclosed approximately 9 billion records.",
      "comparability_note_zh": "公司披露约 90 亿条记录。",
      "comparability_note_en": "The company disclosed approximately 9 billion records.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "patient_visits_covered",
      "label": "医疗记录覆盖就诊人次",
      "label_en": "Patient visits covered",
      "period": "2026-03-31",
      "value": 1.32,
      "currency": "N/A",
      "unit": "billion visits",
      "comparability_note": "The disclosed coverage exceeded 1.32 billion patient visits.",
      "comparability_note_zh": "披露口径为覆盖超过 13.2 亿人次就诊。",
      "comparability_note_en": "The disclosed coverage exceeded 1.32 billion patient visits.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 3
    }
  ],
  "cash_flow": [
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "FY2022",
      "period_start": "2021-04-01",
      "period_end": "2022-03-31",
      "value": -614.676,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0728/2022072801344.pdf",
      "pdf_page": 151
    },
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "FY2023",
      "period_start": "2022-04-01",
      "period_end": "2023-03-31",
      "value": -357.013,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0727/2023072701144.pdf",
      "pdf_page": 155
    },
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "FY2024",
      "period_start": "2023-04-01",
      "period_end": "2024-03-31",
      "value": -326.383,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0726/2024072600647.pdf",
      "pdf_page": 166
    },
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "FY2025",
      "period_start": "2024-04-01",
      "period_end": "2025-03-31",
      "value": -248.814,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501437.pdf",
      "pdf_page": 176
    },
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "FY2026",
      "period_start": "2025-04-01",
      "period_end": "2026-03-31",
      "value": -21.998,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "net_operating_cash_flow",
      "label": "经营活动现金流净额",
      "label_en": "Net operating cash flow",
      "period": "H2 FY2026",
      "value": 29.3,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 2
    },
    {
      "metric_id": "cash_and_cash_equivalents",
      "label": "现金及现金等价物",
      "label_en": "Cash and cash equivalents",
      "period": "2026-03-31",
      "value": 664.764,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 26
    },
    {
      "metric_id": "term_deposits",
      "label": "定期存款",
      "label_en": "Term deposits",
      "period": "2026-03-31",
      "value": 1392.61,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 26
    }
  ],
  "shareholder_returns": [
    {
      "metric_id": "final_dividend_per_share",
      "label": "拟派末期股息",
      "label_en": "Proposed final dividend",
      "period": "FY2026",
      "value": 0.04,
      "currency": "HKD",
      "unit": "per share",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 22
    },
    {
      "metric_id": "shares_repurchased",
      "label": "年内回购股份",
      "label_en": "Shares repurchased during the year",
      "period": "FY2026",
      "value": 50.015,
      "currency": "N/A",
      "unit": "million shares",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 21
    },
    {
      "metric_id": "repurchase_consideration",
      "label": "股份回购总代价",
      "label_en": "Aggregate share-repurchase consideration",
      "period": "FY2026",
      "value": 283.535,
      "currency": "HKD",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000111.pdf",
      "pdf_page": 21
    }
  ],
  "publication_relationship": {
    "type": "unpaid_pilot",
    "labelZh": "免费试点页面",
    "labelEn": "Unpaid pilot profile",
    "disclosureZh": "本页为 PureIR 免费试点页面，由 PureIR 根据正式披露独立整理；公司未付费委托，也未参与评级或投资判断。",
    "disclosureEn": "This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement."
  }
}